Introduction
SuperGen/MGI Pharma's Dacogen and Celgene's Revlimid are in pre-registration for treatment of myelodysplastic syndrome (MDS). However, the former's similar efficacy and toxicity to Pharmion's Vidaza, the first drug indicated for MDS, coupled with the limited target population of the Revlimid, will leave a significant proportion of the MDS population underserved by pharmacotherapy.
Scope
Overview of MDS epidemiology, classification and staging, prognosis and risk factors
Examination of unmet needs in MDS treatment and market opportunities for drug developers
Review of current treatment controversies and physician opinion of existing and future treatment strategies
Profile of the therapeutic and commercial potential of pipeline drugs
Highlights
MDS can affect all ages but is predominantly found in the elderly, with the Aplastic Anemia & MDS International Foundation estimating that 80% of those affected are over 60 years of age. Consequently as a result of the elderly suffering more co-morbidities and poorer prognosis, the current treatment of MDS consists mainly of supportive care.
In the years following Dacogen's anticipated US launch in 2006, Datamonitor predicts the sales margin between it and Vidaza will narrow as physicians gain familiarity with Dacogen and SuperGen/MGI Pharma establish more convenient dosing regimens. However, Vidaza is still predicted to maintain a market lead over its closest direct competitor.
Recently recommended by the FDA's Advisory Committee for accelerated approval, Revlimid looks certain to enter the MDS market in 2006. Indicated for lower-risk MDS in the presence of a chromosome abnormality known as 5q-, Revlimid will quickly become the standard treatment in this patient cohort with additional off-label use also predicted.
Reasons to Purchase
Understand current controversies in MDS treatment and adopt knowledge from this report to drive strategic planning for novel MDS therapeutics
Assess opportunities and risks for innovative treatments within the MDS market
Gain insight into current treatment paradigms, as reported by leading oncologists/ hematologists
(0 items)
